China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension

Last updated: May 31, 2019
Sponsor: Jun Tao
Overall Status: Active - Recruiting

Phase

4

Condition

Circulation Disorders

Stress

Williams Syndrome

Treatment

N/A

Clinical Study ID

NCT03532620
BZ-1702
  • Ages 18-80
  • All Genders

Study Summary

The primary purpose of this trial is to test the hypothesis that Pitavastatin treatment compared to Atorvastatin, in patients with dyslipidemia, prediabetes and hypertension, will have less adverse effect on Hemoglobin A1C (HbA1C), which represents long-term glucose metabolism.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18-80 years old;

  2. IFG: 5.6mmol/L (100mg/dl)≤FPG<7.0mmol/L (126mg/dl), or IGT: 7.8mmol/L (140mg/dl)≤OGTT 2-h PG<11.1mmol/L (200mg/dl), or HbA1C 5.7-6.4% (39-47mmol/mol);

  3. 2.6mmol/L (100mg/dl)≤LDL-C≤5.2mmol/L (200mg/dl), and TG<5.7mmol/L (500mg/dl);

  4. 130mmHg≤SBP<180mmHg, or 80mmHg≤DBP<110mmHg or ongoing anti-hypertensive therapy;

  5. Patients volunteered for the study and signed informed consent.

Exclusion

Exclusion Criteria:

  1. Past history of hypersensitivity to the study drug;

  2. Diagnosed diabetes;

  3. Severe liver disease (including ALT or AST≥2.5-fold the normal upper limit), biliaryobstruction;

  4. Ongoing treatment with cyclosporine within 2 weeks;

  5. Renal dysfunction, including endogenous creatinine clearance male<120ml/min,female<105ml/min, serum creatinine≥2mg/dl (186umol/L), Renal function progressivedecline, GFR<30ml•min-1•1.73m-2;

  6. Diagnosed or past history of ASCVD (including ACS, SCAD, revascularization, ICM,ischemic stroke, TIA, PASD, etc.

  7. SBP≥180mmHg, or DBP≥110mmHg;

  8. Ongoing treatment with Beta blockers, Diuretic;

  9. Secondary hypertension, including SAS, PA, RAS, pheochromocytoma, Cushing's syndrome,aorta diseases, drug induced hypertension;

  10. Ongoing treatment with statins, fibrates, and/or cation exchange resins within 2weeks;

  11. Pancreatic disease;

  12. History of gastrectomy, short bowel syndrome;

  13. Ongoing hormone replacement therapy;

  14. Diagnosed or suspected malignant tumor;

  15. Familial hypercholesterolemia;

  16. Any diseases may limit the efficacy or safety of the study;

  17. Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes tobecome pregnant during study participation;

  18. Patient who was not judged as eligible by the investigator/coinvestigator.

  • IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucosetolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobinA1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolicblood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, ASTaspartate aminotransferase, GFR glomerular filtration rate, ASCVDarteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stablecoronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemicattack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PAprimary aldosteronism, RAS renal arterial stenosis

Study Design

Total Participants: 396
Study Start date:
August 09, 2018
Estimated Completion Date:
September 30, 2020

Study Description

Within the 12 months of the study procedure, the 3rd month is what we called the "check point". At this point, participants' plasma LDL-C will be measured whether it reached individual standard or not. If the results didn't meet the particular LDL-C standard, the participants would be adjusted the drug dosage (pitavastatin 4mg/day, atorvastatin 40mg/day).

Connect with a study center

  • Fourth People's Hospital of Chongqing

    Chongqing, Chongqing 400014
    China

    Active - Recruiting

  • First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong 510630
    China

    Active - Recruiting

  • First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong 510000
    China

    Active - Recruiting

  • Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong 510260
    China

    Active - Recruiting

  • Shenzhen People's Hospital

    Shenzhen, Guangdong 518020
    China

    Site Not Available

  • People's Hospital of Zhongshan City

    Zhongshan, Guangdong 528403
    China

    Active - Recruiting

  • First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan 450052
    China

    Active - Recruiting

  • Yichang Central Hospital

    Yichang, Hubei 443003
    China

    Active - Recruiting

  • Taizhou Hospital of TCM

    Taizhou, Jiangsu 214504
    China

    Active - Recruiting

  • Wuxi People's Hospital

    Wuxi, Jiangsu 214023
    China

    Active - Recruiting

  • Subei People's Hospital of Jiangsu province

    Yangzhou, Jiangsu 225001
    China

    Site Not Available

  • Lanzhou University Second Hospital

    Lanzhou, Qinghai 730030
    China

    Active - Recruiting

  • Yantaishan Hospital, Yantai

    Yantai, Shandong 264001
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.